Asia-Pacific Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Report from 2021 To 2027, Application Scope, Growth Drivers, Insights, Market Report.

The Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market is anticipated to grow significantly at a CAGR of 3.5% over the forecast period (2020-2026). China, India, Japan, ASEAN, South Korea, and the Rest of Asia-Pacific are the major countries contributing to the growth of the Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors industry over the forecast period. The high prevalence of diabetes among the people in the region further supports the market growth. As per the International Diabetes Federation, over 250 million people in the region suffer from diabetes. Among these major economies of the region, China, India, and Japan are the most affected countries. China has the highest prevalence of diabetes in 2019 with around 116 million, India has the second-highest prevalence of diabetes followed by Japan, which significantly contributes to market growth.

(Get 15% Discount on Buying this Report)

Get Report Sample Copy @ https://www.omrglobal.com/request-sample/asia-pacific-dipeptidyl-peptidase-4-inhibitors-market

Some major factors that lead to diabetes in the region are the sedentary lifestyles of the people, the consumption of junk food which leads to obesity, and the rising geriatric population. Hence, such aforementioned factors lead to diabetes in the people which in turn creates a wide scope for the growth of the Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market. Some of the drugs available and approved in the region include Gemigliptin approved in Korea by LG Life Sciences; Anagliptin approved in Japan by Sanwa Kagaku Kenkyusho Co., Ltd., and Kowa Company, Ltd; Trelagliptin, Teneligliptin approved in Japan; and Evogliptin approved for use in South Korea. Hence, such factors are considered to be as growth aspects for the market in the Asia-Pacific region.

A Full Report of Asia-Pacific Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-dipeptidyl-peptidase-4-inhibitors-market

Market Coverage

Market number available for – 2019-2026
Base year- 2019
Forecast period- 2020-2026
Segment Covered- By Type
Regions Covered- Asia-Pacific

Asia-Pacific Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Segmentation

By Type

Sitagliptin
Vildagliptin
Saxagliptin
Linagliptin
Gemigliptin
Anagliptin
Teneligliptin
Others

Asia-Pacific Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Countries Covered

China
India
Japan
ASEAN
South Korea
Rest of Asia-Pacific

Reasons to Buying From us –

We cover more than 15 major industries, further segmented into more than 90 sectors.
More than 120 countries are for analysis.
Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-dipeptidyl-peptidase-4-inhibitors-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.